Showing 6 posts of 6 posts found.


Lilly and Incyte’s atopic dermatitis drug shows promise at Phase 3

February 13, 2020
Sales and Marketing Eli Lilly, Incyte, baricitinib, pharma

Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib …


Lilly’s arthritis drug found to prevent potentially lethal stem cell transplant complications

April 25, 2018
Research and Development Cancer, Eli Lilly, JAK inhibitors, Stem cells, baricitinib, graft-versus-host disease, pharma

Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of a particular Janus Kinase …

Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns

April 20, 2018
Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis

Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …


Lilly gets second shot at application for ‘blockbuster’ arthritis drug

August 31, 2017
Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical

Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …


Lilly awaits FDA review of new arthritis treatment

January 20, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis

Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …

Lilly/Incyte RA drug bests Humira in Phase III trial

November 10, 2015
Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis

Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …

Latest content